K
Kenneth He Huang
Researcher at Durham University
Publications - 28
Citations - 789
Kenneth He Huang is an academic researcher from Durham University. The author has contributed to research in topics: Cancer & Heat shock protein. The author has an hindex of 13, co-authored 28 publications receiving 746 citations.
Papers
More filters
Journal ArticleDOI
Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents.
Kenneth He Huang,James Marvin Veal,Patrick Fadden,John W. Rice,Jeron Eaves,Jon-Paul Strachan,Amy F. Barabasz,Briana Foley,Barta Thomas E,Wei Ma,Melanie Silinski,Mei Hu,Jeffrey M. Partridge,Anisa Scott,Laura G. Dubois,Tiffany Freed,Paul M. Steed,Andy J. Ommen,Emilie D. Smith,Philip F. Hughes,Angela R. Woodward,Hanson Gunnar J,W. Stephen Mccall,Christopher John Markworth,Lindsay Hinkley,Matthew Jenks,Geng Lifeng,Meredith Lewis,James C. Otto,Bert Pronk,Katleen Verleysen,Steven E. Hall +31 more
TL;DR: A novel class of heat shock protein 90 (Hsp90) inhibitors was developed from an unbiased screen to identify protein targets for a diverse compound library, and optimized analogues exhibited nanomolar antiproliferative activity across multiple cancer cell lines.
Journal ArticleDOI
Small molecule inhibitors of Hsp90 potently affect inflammatory disease pathways and exhibit activity in models of rheumatoid arthritis.
John W. Rice,James Marvin Veal,Patrick Fadden,Amy F. Barabasz,Jeffrey M. Partridge,Barta Thomas E,Laura G. Dubois,Kenneth He Huang,Sarah R. Mabbett,Melanie Silinski,Paul M. Steed,Steven E. Hall +11 more
TL;DR: The present results demonstrate that a small molecule Hsp90 inhibitor can impact inflammatory disease processes and provides preclinical validation for consideration of Hsp 90 inhibitors in the treatment of RA.
Journal ArticleDOI
Application of Chemoproteomics to Drug Discovery: Identification of a Clinical Candidate Targeting Hsp90.
Patrick Fadden,Kenneth He Huang,James Marvin Veal,Paul M. Steed,Amy F. Barabasz,Briana Foley,Mei Hu,Jeffrey M. Partridge,John W. Rice,Anisa Scott,Laura G. Dubois,Tiffany Freed,Melanie Silinski,Barta Thomas E,Philip F. Hughes,Andy J. Ommen,Wei Ma,Emilie D. Smith,Angela Woodward Spangenberg,Jeron Eaves,Hanson Gunnar J,Lindsay Hinkley,Matthew Jenks,Meredith Lewis,James C. Otto,Gijsbertus J. Pronk,Katleen Verleysen,Timothy A.J. Haystead,Steven E. Hall +28 more
TL;DR: The chemoproteomics-based approach, which also provides broad target selectivity information, was used to drive the identification of a potent and orally active Hsp90 inhibitor, SNX-5422, which is currently in phase 1 clinical studies.
Journal ArticleDOI
Discovery of benzamide tetrahydro-4H-carbazol-4-ones as novel small molecule inhibitors of Hsp90.
Barta Thomas E,James Marvin Veal,John W. Rice,Jeffrey M. Partridge,Patrick Fadden,Wei Ma,Matthew Jenks,Geng Lifeng,Hanson Gunnar J,Kenneth He Huang,Amy F. Barabasz,Briana Foley,James C. Otto,Steven E. Hall +13 more
TL;DR: X-ray data show that the scaffold binds competitively at the ATP site on Hsp90, and cellular proliferation and client assays demonstrate that members of the series are able to inhibit HSp90 at nanomolar concentrations.
Patent
Tetrahydroindolone and tetrahydroindazolone derivatives
Kenneth He Huang,Jeron Eaves,James Marvin Veal,Thomas E. Barta,Geng Lifeng,Lindsay Hinkley,Hanson Gunnar J +6 more
TL;DR: In this paper, compounds and pharmaceutically acceptable salts of Formula (I) are defined as A, Q1, Q2, Q3, R31, and R41.